BLTE Belite Bio
- 49.650
- +0.050+0.10%
Belite Bio News
Estimating The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE)
H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $59
H.C. Wainwright analyst Yi Chen maintains $Belite Bio(BLTE.US)$ with a buy rating, and maintains the target price at $59.According to TipRanks data, the analyst has a success rate of 27.2% and a total
Express News | Belite Bio Announces That Its Lead Pipeline, Tinlarebant, Has Been Granted Sakigake Designation By The Ministry Of Health, Labour And Welfare In Japan For The Treatment Of STGD1
Express News | Belite: Lead Pipeline, Tinlarebant, Been Granted Sakigake Designation by Ministry of Health, Labour & Welfare in Japan (Mhlw) for Treatment of Stgd1.
Express News | Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
Form 144 | Belite Bio(BLTE.US) Insider Proposes to Sell 1.46 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 4, $Belite Bio(BLTE.US)$ Insider Nathan Mata intends to sell 30,000 shares of its common stock on Jun 4, with a total market value of approximately $1.46 million. Nathan
Form 144 | Belite Bio(BLTE.US) Insider Proposes to Sell 2.33 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 30, $Belite Bio(BLTE.US)$ Insider Yu-Hsin Lin intends to sell 50,000 shares of its common stock on May 30, with a total market value of approximately $2.33 million. Sour
Form 144 | Belite Bio(BLTE.US) Insider Proposes to Sell 641.25K in Common Stocks
SEC FILLINGS DISCLOSED/ May 17, $Belite Bio(BLTE.US)$ Insider Nathan Mata intends to sell 15,000 shares of its common stock on May 20, with a total market value of approximately $641.25K. Nathan Mat
Form 144 | Belite Bio(BLTE.US) Insider Proposes to Sell 1.49 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 16, $Belite Bio(BLTE.US)$ Insider Ching Chen Chiu intends to sell 35,000 shares of its common stock on May 16, with a total market value of approximately $1.49 million.
Buy Rating Affirmed for Belite Bio, Inc. on Strong Clinical Trials and Solid Financial Footing
Express News | Benchmark Reiterates Buy on Belite Bio, Maintains $57 Price Target
Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), CareCloud (CCLD)
Buy Rating Affirmed for Belite Bio, Inc. ADR on Strong Financials and Promising Stargardt Disease Drug Prospects
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $59 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $59 price target.
Express News | Cantor Fitzgerald Reiterates Overweight on Belite Bio
Belite Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 — Cantor Fitzgerald Reiterates → Overweight 03/22/2024 43.2% HC Wainwright & Co. $59 → $59 Mai
Buy Rating Affirmed for Belite Bio, Inc. ADR on Promising Tinlarebant Trials and Potential Stargardt Disease Treatment
Earnings Call Summary | Belite Bio(BLTE.US) Q1 2024 Earnings Conference
The following is a summary of the Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript:Financial Performance:Belite Bio reported Q1 2024 R&D expenses of $6.8 million, a rise from $5.7 million in Q1
Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript
Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript
Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerativ
Analysis
Price Target
No Data
